Suppr超能文献

评估一种用于分析肝细胞癌患者血浆仑伐替尼浓度的毛细管微采样装置。

Evaluation of a Capillary Microsampling Device for Analyzing Plasma Lenvatinib Concentration in Patients With Hepatocellular Carcinoma.

机构信息

Faculty of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.

Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan; and.

出版信息

Ther Drug Monit. 2022 Dec 1;44(6):771-776. doi: 10.1097/FTD.0000000000001013.

Abstract

BACKGROUND

The anticancer drug, Lenvima (lenvatinib), has severe side effects. Therapeutic drug monitoring helps ensure its efficacy and safety. Regular and optimally timed blood sampling is tough, especially when lenvatinib is self-medicated. Microsampling using the easy to handle Microsampling Wing (MSW) may help circumvent this problem. However, current lenvatinib detection methods are not sensitive enough to detect its concentrations in microsamples (<50-250 μL). Thus, the aim of this study was 2-fold (1) develop an analytic method to estimate plasma lenvatinib concentrations in microsamples and (2) verify whether this method works on micro (5.6 μL) blood plasma samples obtained clinically through MSW from patients with unresectable hepatocellular carcinoma (HCC).

METHODS

A simple, highly sensitive, and specific liquid chromatography-electrospray ionization tandem mass spectrometry method was developed. Using this novel protocol, the trough blood plasma concentration of lenvatinib was measured for both blood sampled conventionally and that using MSW. Thirty-five venous whole blood samples were obtained from 11 patients with HCC. Furthermore, the stability of lenvatinib in MSW samples during storage was evaluated.

RESULTS

The mean plasma lenvatinib concentration estimates were not significantly different between the MSW and conventional venous blood samples. CV for interday and intraday assays was low. Up to day 5, the lenvatinib concentration in the MSW samples was 85%-115% of the initial day concentration (when stored at 25°C or 4°C). The interference of endogenous matrix components in the human plasma was low.

CONCLUSIONS

These results indicate that the novel mass spectrometry protocol accurately measures lenvatinib in human plasma and is reproducible. Thus, MSW could be a useful microsampling device for lenvatinib therapeutic drug monitoring in patients with HCC when used in combination with this novel liquid chromatography-electrospray ionization tandem mass spectrometry detection method.

摘要

背景

抗癌药物乐卫玛(仑伐替尼)有严重的副作用。治疗药物监测有助于确保其疗效和安全性。定期和最佳时间的采血很困难,尤其是当仑伐替尼是自我用药时。使用易于操作的 Microsampling Wing(MSW)进行微量采样可能有助于解决这个问题。然而,目前的仑伐替尼检测方法不够灵敏,无法检测微样本(<50-250μL)中的浓度。因此,本研究的目的有两个方面:(1)开发一种分析方法来估计微样本中仑伐替尼的血浆浓度;(2)验证该方法是否适用于通过 MSW 从不可切除的肝细胞癌(HCC)患者获得的临床微(5.6μL)血浆样本。

方法

开发了一种简单、灵敏、特异的液相色谱-电喷雾串联质谱法。使用该新方案,对常规采血和 MSW 采血的仑伐替尼谷血浆浓度进行了测量。从 11 名 HCC 患者中获得了 35 份静脉全血样本。此外,还评估了 MSW 样本中仑伐替尼在储存过程中的稳定性。

结果

MSW 和常规静脉血样本的仑伐替尼血浆浓度估算值无显著差异。日内和日间测定的 CV 较低。在第 5 天,MSW 样本中的仑伐替尼浓度为初始日浓度的 85%-115%(当在 25°C 或 4°C 下储存时)。内源性基质成分对人血浆的干扰较低。

结论

这些结果表明,新的质谱法方案可准确测量人血浆中的仑伐替尼,且重现性好。因此,当与新的液相色谱-电喷雾串联质谱检测方法联合使用时,MSW 可能成为 HCC 患者仑伐替尼治疗药物监测的有用微量采样装置。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验